| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.4 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.045 | 0.4 |